PT-141
ALSO KNOWN AS · Bremelanotide · Vyleesi
An MC4R-directed melanocortin agonist approved by the FDA in 2019 for hypoactive sexual desire disorder in premenopausal women. It acts centrally on arousal pathways rather than on vascular blood flow.
Clinical evidence
The RECONNECT Phase 3 programme showed statistically significant improvements in desire and reduced distress scores versus placebo, with modest effect sizes.
Safety
Nausea is common, affecting roughly 40% of users in trials. Transient blood-pressure increases mean it is not recommended in uncontrolled hypertension.
PRIMARY SOURCES
- 01Vyleesi prescribing information— U.S. FDA
- 02RECONNECT Phase 3 trials— Obstetrics & Gynecology
Educational reference only. Trial figures are protocol-condition means, not individual predictions. Investigational compounds are not approved medicines and have no legitimate consumer supply route.